Fig. 4

Progression-free survival by genetic status. A, the presence of HRD was associated with an improved PFS compared with cases without HRD. B, Similarly, cases with HRR gene or BRCA mutation had longer median PFS than subjects without mutation in HRR gene and BRCA. C, Patients with mutations in the DBD domain of BRCA1 are less sensitive to platinum chemotherapy